This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-125a-5p | AIFM1 | -0.01 | 0.99489 | 0.25 | 0.67324 | miRanda | -0.21 | 0.00378 | NA | |
2 | hsa-miR-125b-5p | AIFM1 | 0.01 | 0.99415 | 0.25 | 0.67324 | miRNATAP | -0.11 | 0.01066 | NA | |
3 | hsa-miR-145-5p | AIFM1 | 0.27 | 0.76637 | 0.25 | 0.67324 | miRNATAP | -0.13 | 0.00193 | 20332243 | Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death |
4 | hsa-miR-29a-3p | AKT2 | 0.2 | 0.85995 | -0.01 | 0.98435 | MirTarget | -0.12 | 0.00214 | 24076586 | Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis |
5 | hsa-miR-106a-5p | AKT3 | -0.82 | 0.02545 | 0.09 | 0.82989 | miRNATAP | -0.16 | 0.00858 | NA | |
6 | hsa-miR-106b-5p | AKT3 | -0.39 | 0.38964 | 0.09 | 0.82989 | miRNATAP | -0.31 | 0.00102 | NA | |
7 | hsa-miR-107 | AKT3 | -0.29 | 0.76966 | 0.09 | 0.82989 | PITA; miRanda | -0.29 | 0.00414 | NA | |
8 | hsa-miR-335-3p | AKT3 | 0.07 | 0.89349 | 0.09 | 0.82989 | mirMAP | -0.16 | 0.00961 | NA | |
9 | hsa-miR-93-5p | AKT3 | -0.38 | 0.73231 | 0.09 | 0.82989 | miRNATAP | -0.27 | 0.00266 | NA | |
10 | hsa-miR-23b-3p | APAF1 | 0.19 | 0.84836 | 0.26 | 0.50442 | miRNATAP | -0.1 | 0.00576 | NA | |
11 | hsa-let-7a-5p | BCL2 | 0.05 | 0.97156 | 0 | 0.99871 | miRNAWalker2 validate | -0.16 | 0.048 | 24643702; 26915294 | Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl 2 via microRNA let 7a and miR 34b in ovarian cancer cells; Moreover the relative abundance of Bcl-2 and microRNAs let-7a miR-34b expressions were detected by quantitative real-time PCR qRT-PCR and Western blotting; E2 + P4 promoted the expression of let-7a and miR-34b and reduced the expression of Bcl-2 in ovarian cancer cells; When the expression of let-7a or/and miR-34b was inhibited using miRNA inhibitors E2 + P4 treatment did not change the protein level of Bcl-2; E2 + P4 significantly inhibited the cell survival promoted the cell apoptosis induced the expression of let-7a and miR-34b and reduced the expression of Bcl-2 in ovarian cancer cells;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively |
12 | hsa-miR-15b-3p | BCL2 | 0.08 | 0.84632 | 0 | 0.99871 | mirMAP | -0.19 | 0.00394 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
13 | hsa-miR-15b-5p | BCL2 | 0.25 | 0.79071 | 0 | 0.99871 | miRNAWalker2 validate; miRTarBase | -0.22 | 0.00768 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
14 | hsa-miR-192-5p | BCL2 | -0 | 0.99638 | 0 | 0.99871 | miRNAWalker2 validate | -0.12 | 0.01734 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
15 | hsa-miR-21-5p | BCL2 | -0.52 | 0.64199 | 0 | 0.99871 | miRNAWalker2 validate; miRTarBase | -0.15 | 0.00126 | 21468550; 25994220; 25381586; 26555418; 23359184; 22964582; 21376256 | BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
16 | hsa-miR-129-5p | BIRC3 | 0.42 | 0.45424 | -0.01 | 0.98965 | miRanda | -0.22 | 0.00017 | NA | |
17 | hsa-miR-107 | CAPN2 | -0.29 | 0.76966 | -0.22 | 0.75885 | miRanda | -0.16 | 0.00224 | NA | |
18 | hsa-let-7c-5p | CASP3 | -0.2 | 0.87412 | 0.07 | 0.87356 | MirTarget | -0.1 | 0.00027 | NA | |
19 | hsa-miR-101-3p | CASP3 | -0.01 | 0.982 | 0.07 | 0.87356 | MirTarget | -0.14 | 7.0E-5 | NA | |
20 | hsa-miR-30a-5p | CASP3 | -0.16 | 0.8795 | 0.07 | 0.87356 | miRNATAP | -0.1 | 0.00039 | NA | |
21 | hsa-miR-30c-5p | CASP3 | -0.18 | 0.83318 | 0.07 | 0.87356 | miRNATAP | -0.14 | 0.00033 | NA | |
22 | hsa-miR-320c | CASP3 | 0.09 | 0.78554 | 0.07 | 0.87356 | MirTarget; miRanda | -0.1 | 0.00087 | NA | |
23 | hsa-miR-125a-5p | CASP6 | -0.01 | 0.99489 | -0.1 | 0.80319 | miRanda | -0.15 | 0.0371 | NA | |
24 | hsa-miR-106b-5p | CASP7 | -0.39 | 0.38964 | 0.28 | 0.53584 | miRNAWalker2 validate | -0.15 | 0.00046 | 22986525 | MicroRNA 106b 25 cluster expression is associated with early disease recurrence and targets caspase 7 and focal adhesion in human prostate cancer; Moreover increased tumor miR-106b expression was associated with disease recurrence and the combination of high miR-106b and low CASP7 caspase-7 expressions in primary tumors was an independent predictor of early disease recurrence adjusted hazard ratio=4.1; 95% confidence interval: 1.6-12.3; The approach revealed that CASP7 is a direct target of miR-106b which was confirmed by western blot analysis and a 3'-untranslated region reporter assay; Moreover selected phenotypes induced by miR-106b knockdown in DU145 human prostate cancer cells did not develop when both miR-106b and CASP7 expression were inhibited |
25 | hsa-miR-18a-3p | CASP7 | -0.19 | 0.618 | 0.28 | 0.53584 | MirTarget | -0.12 | 0.00095 | NA | |
26 | hsa-miR-125a-3p | CASP9 | 0.12 | 0.80054 | -0.28 | 0.47903 | miRanda | -0.19 | 3.0E-5 | NA | |
27 | hsa-miR-342-5p | CASP9 | -0.2 | 0.63467 | -0.28 | 0.47903 | MirTarget | -0.17 | 3.0E-5 | NA | |
28 | hsa-miR-20a-5p | CHP2 | -0.86 | 0.07026 | -0.33 | 0.64805 | MirTarget | -0.33 | 0.01146 | NA | |
29 | hsa-miR-181c-5p | CSF2RB | -0.26 | 0.64547 | -0.41 | 0.32071 | MirTarget | -0.19 | 0.00892 | NA | |
30 | hsa-miR-361-5p | CYCS | -0.28 | 0.72855 | 0.15 | 0.82426 | miRNAWalker2 validate | -0.16 | 0.01243 | NA | |
31 | hsa-miR-145-5p | DFFA | 0.27 | 0.76637 | -0.21 | 0.66869 | miRNAWalker2 validate; miRTarBase | -0.14 | 1.0E-5 | NA | |
32 | hsa-miR-342-3p | DFFA | -0.23 | 0.73996 | -0.21 | 0.66869 | mirMAP | -0.14 | 0.00044 | NA | |
33 | hsa-miR-365a-3p | DFFB | 0.34 | 0.57709 | -0.28 | 0.38144 | MirTarget | -0.12 | 0.00828 | NA | |
34 | hsa-miR-130b-3p | ENDOD1 | -0.25 | 0.52407 | 0.48 | 0.39107 | MirTarget | -0.21 | 9.0E-5 | NA | |
35 | hsa-miR-181a-5p | ENDOD1 | -0.03 | 0.97581 | 0.48 | 0.39107 | MirTarget | -0.15 | 0.00642 | NA | |
36 | hsa-miR-181b-5p | ENDOD1 | -0.05 | 0.95293 | 0.48 | 0.39107 | MirTarget | -0.18 | 0.00081 | NA | |
37 | hsa-miR-181d-5p | ENDOD1 | -0.29 | 0.60439 | 0.48 | 0.39107 | MirTarget | -0.11 | 0.00565 | NA | |
38 | hsa-miR-26b-5p | ENDOG | 0.16 | 0.79078 | 0.13 | 0.73953 | miRNAWalker2 validate | -0.14 | 0.01892 | NA | |
39 | hsa-miR-361-5p | FADD | -0.28 | 0.72855 | 0.13 | 0.78042 | MirTarget; miRanda; miRNATAP | -0.15 | 0.00056 | NA | |
40 | hsa-miR-129-5p | FAS | 0.42 | 0.45424 | 0.19 | 0.66784 | miRanda | -0.12 | 0.00037 | NA | |
41 | hsa-miR-324-5p | FASLG | -0.36 | 0.49973 | -0.38 | 0.44069 | miRanda | -0.26 | 0.04241 | NA | |
42 | hsa-miR-92a-3p | FASLG | 0.02 | 0.99144 | -0.38 | 0.44069 | miRNATAP | -0.47 | 0.00193 | NA | |
43 | hsa-miR-92b-3p | FASLG | 0.45 | 0.64619 | -0.38 | 0.44069 | miRNATAP | -0.27 | 0.00726 | NA | |
44 | hsa-miR-139-5p | IKBKB | -0.06 | 0.91481 | -0.24 | 0.63061 | miRanda | -0.11 | 0.00111 | NA | |
45 | hsa-miR-125a-3p | IL1A | 0.12 | 0.80054 | -0.62 | 0.11872 | miRanda | -0.3 | 0.01538 | NA | |
46 | hsa-miR-296-3p | IL1B | 0.31 | 0.47034 | -0.59 | 0.17485 | miRNATAP | -0.15 | 0.02531 | NA | |
47 | hsa-miR-30a-3p | IL1B | 0.11 | 0.92065 | -0.59 | 0.17485 | MirTarget | -0.21 | 0.01107 | NA | |
48 | hsa-miR-129-5p | IL1RAP | 0.42 | 0.45424 | 0.32 | 0.56867 | miRanda | -0.11 | 0.00324 | NA | |
49 | hsa-miR-93-5p | IL1RAP | -0.38 | 0.73231 | 0.32 | 0.56867 | MirTarget | -0.13 | 0.04658 | NA | |
50 | hsa-miR-1226-3p | IRAK1 | -0.04 | 0.94275 | -0.36 | 0.59789 | miRNAWalker2 validate | -0.11 | 0.00112 | NA | |
51 | hsa-miR-92a-3p | IRAK1 | 0.02 | 0.99144 | -0.36 | 0.59789 | miRNAWalker2 validate | -0.16 | 0.00421 | NA | |
52 | hsa-miR-335-3p | IRAK3 | 0.07 | 0.89349 | -0.17 | 0.62581 | mirMAP | -0.1 | 0.03752 | NA | |
53 | hsa-miR-129-5p | NFKB1 | 0.42 | 0.45424 | 0.05 | 0.9202 | PITA; miRanda | -0.11 | 1.0E-5 | NA | |
54 | hsa-let-7d-5p | NGF | 0.01 | 0.98839 | 0.06 | 0.86885 | MirTarget | -0.39 | 7.0E-5 | NA | |
55 | hsa-let-7f-5p | NGF | -0.4 | 0.69537 | 0.06 | 0.86885 | MirTarget | -0.17 | 0.013 | NA | |
56 | hsa-let-7g-5p | NGF | -0.32 | 0.66036 | 0.06 | 0.86885 | MirTarget | -0.37 | 5.0E-5 | NA | |
57 | hsa-let-7i-5p | NGF | -0.09 | 0.90231 | 0.06 | 0.86885 | MirTarget | -0.24 | 0.01497 | NA | |
58 | hsa-miR-320b | NGF | 0.3 | 0.70045 | 0.06 | 0.86885 | miRanda | -0.18 | 0.02089 | NA | |
59 | hsa-miR-429 | NGF | -0.6 | 0.12897 | 0.06 | 0.86885 | miRanda | -0.22 | 0.00171 | NA | |
60 | hsa-miR-98-5p | NGF | -0.05 | 0.91078 | 0.06 | 0.86885 | MirTarget | -0.19 | 0.00656 | NA | |
61 | hsa-miR-335-3p | PIK3CG | 0.07 | 0.89349 | -0.35 | 0.33299 | mirMAP | -0.16 | 0.00995 | NA | |
62 | hsa-miR-17-5p | PIK3R1 | -0.64 | 0.32067 | 0.18 | 0.73919 | MirTarget; TargetScan; miRNATAP | -0.11 | 0.02188 | NA | |
63 | hsa-miR-221-3p | PIK3R1 | -0.26 | 0.74402 | 0.18 | 0.73919 | MirTarget | -0.21 | 2.0E-5 | NA | |
64 | hsa-miR-222-3p | PIK3R1 | -0.23 | 0.72665 | 0.18 | 0.73919 | MirTarget | -0.21 | 1.0E-5 | NA | |
65 | hsa-miR-629-3p | PIK3R1 | -0.46 | 0.20921 | 0.18 | 0.73919 | MirTarget | -0.18 | 7.0E-5 | NA | |
66 | hsa-miR-28-5p | PIK3R2 | -0.05 | 0.91096 | 0.14 | 0.83378 | miRanda | -0.1 | 0.0459 | NA | |
67 | hsa-miR-423-5p | PIK3R2 | -0.31 | 0.65889 | 0.14 | 0.83378 | MirTarget | -0.12 | 0.02884 | NA | |
68 | hsa-miR-1271-5p | PIK3R3 | -0.12 | 0.70353 | -0.03 | 0.95678 | mirMAP | -0.2 | 0.0004 | NA | |
69 | hsa-miR-92a-3p | PIK3R3 | 0.02 | 0.99144 | -0.03 | 0.95678 | MirTarget; miRNATAP | -0.3 | 0.00023 | NA | |
70 | hsa-miR-92b-3p | PIK3R3 | 0.45 | 0.64619 | -0.03 | 0.95678 | MirTarget; miRNATAP | -0.18 | 0.00061 | NA | |
71 | hsa-miR-194-5p | PPP3CA | -0.14 | 0.80907 | 0.26 | 0.60892 | MirTarget | -0.14 | 1.0E-5 | NA | |
72 | hsa-miR-30c-5p | PPP3CA | -0.18 | 0.83318 | 0.26 | 0.60892 | miRNATAP | -0.12 | 0.01001 | NA | |
73 | hsa-miR-93-3p | PPP3CA | -0.02 | 0.96068 | 0.26 | 0.60892 | miRNATAP | -0.11 | 0.0175 | NA | |
74 | hsa-miR-93-5p | PPP3CA | -0.38 | 0.73231 | 0.26 | 0.60892 | miRNATAP | -0.14 | 0.00165 | NA | |
75 | hsa-miR-16-5p | PPP3CB | -0.2 | 0.74283 | 0.15 | 0.76092 | miRNATAP | -0.1 | 0.00014 | NA | |
76 | hsa-miR-361-5p | PPP3CB | -0.28 | 0.72855 | 0.15 | 0.76092 | miRanda | -0.11 | 0.01141 | NA | |
77 | hsa-miR-361-5p | PPP3CC | -0.28 | 0.72855 | 0.02 | 0.93808 | miRanda | -0.13 | 0.0292 | NA | |
78 | hsa-miR-141-3p | PRKACB | -0.37 | 0.42836 | -0.12 | 0.76286 | MirTarget; TargetScan; miRNATAP | -0.15 | 0.00014 | NA | |
79 | hsa-miR-200a-3p | PRKACB | -0.8 | 0.14799 | -0.12 | 0.76286 | MirTarget; miRNATAP | -0.15 | 0 | NA | |
80 | hsa-miR-200b-3p | PRKACB | -0.53 | 0.55597 | -0.12 | 0.76286 | MirTarget; TargetScan | -0.13 | 2.0E-5 | NA | |
81 | hsa-miR-200c-3p | PRKACB | -0.33 | 0.81383 | -0.12 | 0.76286 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
82 | hsa-miR-30e-3p | PRKACB | 0.2 | 0.85742 | -0.12 | 0.76286 | mirMAP | -0.12 | 0.02604 | NA | |
83 | hsa-miR-342-3p | PRKAR1B | -0.23 | 0.73996 | -0.14 | 0.74922 | mirMAP | -0.11 | 0.03635 | NA | |
84 | hsa-miR-625-5p | PRKAR1B | -0.73 | 0.06055 | -0.14 | 0.74922 | mirMAP | -0.13 | 5.0E-5 | NA | |
85 | hsa-miR-92a-3p | PRKAR2A | 0.02 | 0.99144 | -0.08 | 0.85066 | mirMAP | -0.12 | 0.01023 | NA | |
86 | hsa-miR-107 | PRKAR2B | -0.29 | 0.76966 | 0.13 | 0.76775 | miRanda | -0.25 | 0.0006 | NA | |
87 | hsa-miR-186-5p | PRKAR2B | -0.25 | 0.70131 | 0.13 | 0.76775 | mirMAP | -0.21 | 0.00774 | NA | |
88 | hsa-miR-200b-3p | PRKAR2B | -0.53 | 0.55597 | 0.13 | 0.76775 | TargetScan | -0.1 | 0.03574 | NA | |
89 | hsa-miR-200c-3p | PRKAR2B | -0.33 | 0.81383 | 0.13 | 0.76775 | miRNATAP | -0.14 | 0.0066 | NA | |
90 | hsa-miR-361-5p | PRKAR2B | -0.28 | 0.72855 | 0.13 | 0.76775 | miRanda | -0.23 | 0.01527 | NA | |
91 | hsa-miR-129-5p | TNFRSF10A | 0.42 | 0.45424 | -0.25 | 0.36985 | miRanda | -0.14 | 0.00011 | NA | |
92 | hsa-miR-145-5p | TNFRSF10A | 0.27 | 0.76637 | -0.25 | 0.36985 | MirTarget | -0.17 | 0.00149 | NA | |
93 | hsa-miR-940 | TNFRSF10B | 0.19 | 0.67975 | -0.16 | 0.73185 | miRNAWalker2 validate | -0.12 | 0.00013 | NA | |
94 | hsa-miR-146b-5p | TNFRSF10D | 0.03 | 0.96457 | -0.39 | 0.25531 | mirMAP | -0.19 | 0.00133 | NA | |
95 | hsa-miR-26a-5p | TNFRSF10D | 0.05 | 0.95522 | -0.39 | 0.25531 | mirMAP | -0.27 | 0.00606 | NA | |
96 | hsa-miR-26b-5p | TNFRSF10D | 0.16 | 0.79078 | -0.39 | 0.25531 | mirMAP | -0.22 | 0.02108 | NA | |
97 | hsa-miR-129-5p | TNFSF10 | 0.42 | 0.45424 | -0.2 | 0.77958 | miRanda | -0.18 | 0.00111 | NA | |
98 | hsa-miR-139-5p | TNFSF10 | -0.06 | 0.91481 | -0.2 | 0.77958 | miRanda | -0.21 | 0.01594 | NA | |
99 | hsa-miR-324-3p | TRADD | -0.24 | 0.713 | 0.14 | 0.73872 | miRNATAP | -0.17 | 0.00028 | NA | |
100 | hsa-miR-181a-2-3p | XIAP | 0.16 | 0.86725 | 0 | 0.99618 | mirMAP | -0.13 | 1.0E-5 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CELL DEATH | 28 | 1001 | 3.159e-25 | 1.47e-21 |
2 | REGULATION OF CELL DEATH | 30 | 1472 | 2.397e-23 | 5.576e-20 |
3 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 32 | 1848 | 4.11e-23 | 6.375e-20 |
4 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 14 | 95 | 2.321e-22 | 2.16e-19 |
5 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 17 | 213 | 2.036e-22 | 2.16e-19 |
6 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 14 | 99 | 4.29e-22 | 3.327e-19 |
7 | APOPTOTIC SIGNALING PATHWAY | 18 | 289 | 8.691e-22 | 5.777e-19 |
8 | ZYMOGEN ACTIVATION | 14 | 112 | 2.66e-21 | 1.547e-18 |
9 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 30 | 1791 | 6.951e-21 | 3.594e-18 |
10 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 27 | 1381 | 4.119e-20 | 1.917e-17 |
11 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 14 | 154 | 2.736e-19 | 1.157e-16 |
12 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 27 | 1492 | 3.036e-19 | 1.177e-16 |
13 | POSITIVE REGULATION OF CELL DEATH | 20 | 605 | 8.134e-19 | 2.911e-16 |
14 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 10 | 39 | 8.777e-19 | 2.917e-16 |
15 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 29 | 1929 | 9.836e-19 | 3.051e-16 |
16 | NEGATIVE REGULATION OF CELL DEATH | 22 | 872 | 2.642e-18 | 7.683e-16 |
17 | REGULATION OF PEPTIDASE ACTIVITY | 17 | 392 | 6.859e-18 | 1.877e-15 |
18 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 26 | 1518 | 7.956e-18 | 2.057e-15 |
19 | PROTEIN MATURATION | 15 | 265 | 1.623e-17 | 3.976e-15 |
20 | INTRACELLULAR SIGNAL TRANSDUCTION | 25 | 1572 | 2.787e-16 | 6.484e-14 |
21 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 13 | 3.583e-16 | 7.94e-14 |
22 | REGULATION OF PROTEOLYSIS | 19 | 711 | 3.897e-16 | 8.242e-14 |
23 | POSITIVE REGULATION OF PROTEOLYSIS | 15 | 363 | 1.76e-15 | 3.561e-13 |
24 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 17 | 4.034e-15 | 7.82e-13 |
25 | RESPONSE TO CYTOKINE | 18 | 714 | 7.941e-15 | 1.478e-12 |
26 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 98 | 1.755e-14 | 3.141e-12 |
27 | POSITIVE REGULATION OF CELL COMMUNICATION | 23 | 1532 | 2.732e-14 | 4.708e-12 |
28 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 22 | 3.507e-14 | 5.828e-12 |
29 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 18 | 799 | 5.477e-14 | 8.787e-12 |
30 | RESPONSE TO NITROGEN COMPOUND | 18 | 859 | 1.882e-13 | 2.919e-11 |
31 | REGULATION OF HYDROLASE ACTIVITY | 21 | 1327 | 2.173e-13 | 3.261e-11 |
32 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 18 | 905 | 4.558e-13 | 6.628e-11 |
33 | IMMUNE SYSTEM PROCESS | 24 | 1984 | 6.529e-13 | 9.206e-11 |
34 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 7 | 33 | 8.621e-13 | 1.146e-10 |
35 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 7 | 33 | 8.621e-13 | 1.146e-10 |
36 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 7 | 34 | 1.084e-12 | 1.401e-10 |
37 | RESPONSE TO ENDOGENOUS STIMULUS | 21 | 1450 | 1.211e-12 | 1.524e-10 |
38 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 153 | 1.642e-12 | 2.011e-10 |
39 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 14 | 505 | 4.098e-12 | 4.89e-10 |
40 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 10 | 171 | 5.007e-12 | 5.824e-10 |
41 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 12 | 321 | 5.685e-12 | 6.452e-10 |
42 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 10 | 179 | 7.902e-12 | 8.754e-10 |
43 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 21 | 1618 | 9.912e-12 | 1.073e-09 |
44 | NEURON DEATH | 7 | 47 | 1.239e-11 | 1.31e-09 |
45 | CYTOKINE MEDIATED SIGNALING PATHWAY | 13 | 452 | 1.746e-11 | 1.805e-09 |
46 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 10 | 200 | 2.379e-11 | 2.359e-09 |
47 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 363 | 2.383e-11 | 2.359e-09 |
48 | HOMEOSTATIC PROCESS | 19 | 1337 | 3.061e-11 | 2.967e-09 |
49 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 7 | 55 | 3.944e-11 | 3.745e-09 |
50 | RESPONSE TO ABIOTIC STIMULUS | 17 | 1024 | 4.289e-11 | 3.992e-09 |
51 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 14 | 606 | 4.649e-11 | 4.16e-09 |
52 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 16 | 876 | 4.622e-11 | 4.16e-09 |
53 | RESPONSE TO HORMONE | 16 | 893 | 6.147e-11 | 5.397e-09 |
54 | REGULATION OF KINASE ACTIVITY | 15 | 776 | 9.909e-11 | 8.539e-09 |
55 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 10 | 233 | 1.072e-10 | 8.908e-09 |
56 | RESPONSE TO TUMOR NECROSIS FACTOR | 10 | 233 | 1.072e-10 | 8.908e-09 |
57 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 20 | 1656 | 1.408e-10 | 1.149e-08 |
58 | NEURON APOPTOTIC PROCESS | 6 | 35 | 1.629e-10 | 1.307e-08 |
59 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 17 | 1135 | 2.131e-10 | 1.681e-08 |
60 | REGULATION OF PROTEIN MODIFICATION PROCESS | 20 | 1710 | 2.498e-10 | 1.937e-08 |
61 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 16 | 1008 | 3.661e-10 | 2.793e-08 |
62 | PROTEOLYSIS | 17 | 1208 | 5.576e-10 | 4.185e-08 |
63 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 6 | 43 | 6.033e-10 | 4.456e-08 |
64 | RESPONSE TO BIOTIC STIMULUS | 15 | 886 | 6.239e-10 | 4.536e-08 |
65 | RESPONSE TO LIPID | 15 | 888 | 6.436e-10 | 4.607e-08 |
66 | RESPONSE TO PEPTIDE | 11 | 404 | 1.411e-09 | 9.948e-08 |
67 | REGULATION OF TRANSFERASE ACTIVITY | 15 | 946 | 1.534e-09 | 1.065e-07 |
68 | RESPONSE TO BACTERIUM | 12 | 528 | 1.74e-09 | 1.191e-07 |
69 | EXECUTION PHASE OF APOPTOSIS | 6 | 55 | 2.811e-09 | 1.895e-07 |
70 | CELLULAR RESPONSE TO HORMONE STIMULUS | 12 | 552 | 2.87e-09 | 1.908e-07 |
71 | DNA CATABOLIC PROCESS | 5 | 27 | 3.999e-09 | 2.62e-07 |
72 | REGULATION OF IMMUNE RESPONSE | 14 | 858 | 4.29e-09 | 2.773e-07 |
73 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 15 | 1036 | 5.283e-09 | 3.322e-07 |
74 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 15 | 1036 | 5.283e-09 | 3.322e-07 |
75 | CHEMICAL HOMEOSTASIS | 14 | 874 | 5.432e-09 | 3.37e-07 |
76 | RESPONSE TO EXTERNAL STIMULUS | 19 | 1821 | 5.757e-09 | 3.525e-07 |
77 | PHOSPHORYLATION | 16 | 1228 | 6.356e-09 | 3.841e-07 |
78 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 470 | 6.826e-09 | 4.072e-07 |
79 | RESPONSE TO INORGANIC SUBSTANCE | 11 | 479 | 8.305e-09 | 4.892e-07 |
80 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 7 | 118 | 9.2e-09 | 5.351e-07 |
81 | CELLULAR RESPONSE TO PEPTIDE | 9 | 274 | 1.055e-08 | 6.058e-07 |
82 | IMMUNE RESPONSE | 15 | 1100 | 1.185e-08 | 6.704e-07 |
83 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 12 | 1.196e-08 | 6.704e-07 |
84 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 9 | 279 | 1.234e-08 | 6.833e-07 |
85 | T CELL HOMEOSTASIS | 5 | 34 | 1.362e-08 | 7.455e-07 |
86 | PROTEIN PHOSPHORYLATION | 14 | 944 | 1.444e-08 | 7.814e-07 |
87 | CELLULAR GLUCOSE HOMEOSTASIS | 6 | 75 | 1.886e-08 | 1.009e-06 |
88 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 19 | 1977 | 2.223e-08 | 1.175e-06 |
89 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 6 | 80 | 2.791e-08 | 1.459e-06 |
90 | RESPONSE TO OXYGEN LEVELS | 9 | 311 | 3.149e-08 | 1.628e-06 |
91 | APOPTOTIC DNA FRAGMENTATION | 4 | 15 | 3.281e-08 | 1.678e-06 |
92 | ACTIVATION OF IMMUNE RESPONSE | 10 | 427 | 3.634e-08 | 1.838e-06 |
93 | REGULATION OF IMMUNE SYSTEM PROCESS | 16 | 1403 | 4.176e-08 | 2.089e-06 |
94 | POSITIVE REGULATION OF IMMUNE RESPONSE | 11 | 563 | 4.357e-08 | 2.157e-06 |
95 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 152 | 5.323e-08 | 2.607e-06 |
96 | RESPONSE TO METAL ION | 9 | 333 | 5.657e-08 | 2.707e-06 |
97 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 17 | 5.701e-08 | 2.707e-06 |
98 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 4 | 17 | 5.701e-08 | 2.707e-06 |
99 | INFLAMMATORY RESPONSE | 10 | 454 | 6.456e-08 | 3.034e-06 |
100 | RESPONSE TO TOXIC SUBSTANCE | 8 | 241 | 6.958e-08 | 3.237e-06 |
101 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 14 | 1079 | 7.698e-08 | 3.546e-06 |
102 | REGULATION OF RESPONSE TO STRESS | 16 | 1468 | 7.846e-08 | 3.579e-06 |
103 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 13 | 917 | 9.049e-08 | 4.088e-06 |
104 | DNA CATABOLIC PROCESS ENDONUCLEOLYTIC | 4 | 19 | 9.254e-08 | 4.14e-06 |
105 | LYMPHOCYTE HOMEOSTASIS | 5 | 50 | 1.009e-07 | 4.471e-06 |
106 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 9 | 360 | 1.099e-07 | 4.826e-06 |
107 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 51 | 1.117e-07 | 4.856e-06 |
108 | POSITIVE REGULATION OF KINASE ACTIVITY | 10 | 482 | 1.128e-07 | 4.859e-06 |
109 | POSITIVE REGULATION OF DEFENSE RESPONSE | 9 | 364 | 1.208e-07 | 5.108e-06 |
110 | RENAL SYSTEM PROCESS | 6 | 102 | 1.204e-07 | 5.108e-06 |
111 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 1.352e-07 | 5.657e-06 |
112 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 8 | 263 | 1.362e-07 | 5.657e-06 |
113 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 9 | 370 | 1.387e-07 | 5.712e-06 |
114 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 8 | 264 | 1.402e-07 | 5.721e-06 |
115 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 10 | 514 | 2.046e-07 | 8.276e-06 |
116 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 23 | 2.1e-07 | 8.423e-06 |
117 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 59 | 2.348e-07 | 9.336e-06 |
118 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 12 | 829 | 2.518e-07 | 9.846e-06 |
119 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 4 | 24 | 2.516e-07 | 9.846e-06 |
120 | LEUKOCYTE HOMEOSTASIS | 5 | 60 | 2.557e-07 | 9.914e-06 |
121 | APOPTOTIC NUCLEAR CHANGES | 4 | 25 | 2.99e-07 | 1.15e-05 |
122 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 3.327e-07 | 1.269e-05 |
123 | ACTIVATION OF INNATE IMMUNE RESPONSE | 7 | 204 | 3.959e-07 | 1.498e-05 |
124 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 4.227e-07 | 1.586e-05 |
125 | POSITIVE REGULATION OF NEURON DEATH | 5 | 67 | 4.467e-07 | 1.663e-05 |
126 | RESPONSE TO WOUNDING | 10 | 563 | 4.722e-07 | 1.744e-05 |
127 | RESPONSE TO MECHANICAL STIMULUS | 7 | 210 | 4.815e-07 | 1.764e-05 |
128 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 4.856e-07 | 1.765e-05 |
129 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 6 | 132 | 5.561e-07 | 2.006e-05 |
130 | REGULATION OF CATABOLIC PROCESS | 11 | 731 | 5.981e-07 | 2.141e-05 |
131 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 8 | 323 | 6.492e-07 | 2.306e-05 |
132 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 5 | 74 | 7.363e-07 | 2.595e-05 |
133 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 228 | 8.369e-07 | 2.917e-05 |
134 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 4 | 32 | 8.4e-07 | 2.917e-05 |
135 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 6 | 142 | 8.542e-07 | 2.944e-05 |
136 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 6 | 144 | 9.272e-07 | 3.172e-05 |
137 | WOUND HEALING | 9 | 470 | 1.031e-06 | 3.5e-05 |
138 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 10 | 616 | 1.07e-06 | 3.609e-05 |
139 | RENAL WATER HOMEOSTASIS | 4 | 34 | 1.08e-06 | 3.614e-05 |
140 | CELLULAR RESPONSE TO STRESS | 15 | 1565 | 1.182e-06 | 3.928e-05 |
141 | RESPONSE TO OXIDATIVE STRESS | 8 | 352 | 1.238e-06 | 4.086e-05 |
142 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 14 | 1360 | 1.287e-06 | 4.219e-05 |
143 | NIK NF KAPPAB SIGNALING | 5 | 83 | 1.307e-06 | 4.252e-05 |
144 | REGULATION OF INNATE IMMUNE RESPONSE | 8 | 357 | 1.376e-06 | 4.446e-05 |
145 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 7 | 246 | 1.391e-06 | 4.463e-05 |
146 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 5 | 85 | 1.471e-06 | 4.689e-05 |
147 | REGULATION OF NEURON DEATH | 7 | 252 | 1.633e-06 | 5.169e-05 |
148 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 4 | 38 | 1.707e-06 | 5.367e-05 |
149 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 5 | 88 | 1.748e-06 | 5.459e-05 |
150 | LEUKOCYTE CELL CELL ADHESION | 7 | 255 | 1.767e-06 | 5.48e-05 |
151 | NEGATIVE REGULATION OF CELL COMMUNICATION | 13 | 1192 | 1.8e-06 | 5.547e-05 |
152 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 258 | 1.909e-06 | 5.845e-05 |
153 | AGING | 7 | 264 | 2.224e-06 | 6.763e-05 |
154 | RESPONSE TO CARBOHYDRATE | 6 | 168 | 2.278e-06 | 6.883e-05 |
155 | GLUCOSE HOMEOSTASIS | 6 | 170 | 2.44e-06 | 7.278e-05 |
156 | CARBOHYDRATE HOMEOSTASIS | 6 | 170 | 2.44e-06 | 7.278e-05 |
157 | CELLULAR HOMEOSTASIS | 10 | 676 | 2.469e-06 | 7.316e-05 |
158 | DEFENSE RESPONSE | 13 | 1231 | 2.575e-06 | 7.488e-05 |
159 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 95 | 2.555e-06 | 7.488e-05 |
160 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 4 | 42 | 2.571e-06 | 7.488e-05 |
161 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 7 | 272 | 2.71e-06 | 7.832e-05 |
162 | RESPONSE TO CORTICOSTEROID | 6 | 176 | 2.983e-06 | 8.567e-05 |
163 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 11 | 867 | 3.159e-06 | 9.019e-05 |
164 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 3 | 13 | 3.204e-06 | 9.037e-05 |
165 | RESPONSE TO COBALT ION | 3 | 13 | 3.204e-06 | 9.037e-05 |
166 | REGULATION OF GLUCOSE TRANSPORT | 5 | 100 | 3.291e-06 | 9.226e-05 |
167 | REGULATION OF LIPID METABOLIC PROCESS | 7 | 282 | 3.439e-06 | 9.583e-05 |
168 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 4 | 46 | 3.723e-06 | 0.0001029 |
169 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 3.737e-06 | 0.0001029 |
170 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 9 | 552 | 3.859e-06 | 0.0001056 |
171 | REGULATION OF CELL PROLIFERATION | 14 | 1496 | 3.967e-06 | 0.0001079 |
172 | RESPONSE TO ANTIBIOTIC | 4 | 47 | 4.063e-06 | 0.0001089 |
173 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 4.072e-06 | 0.0001089 |
174 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 47 | 4.063e-06 | 0.0001089 |
175 | POSITIVE REGULATION OF GENE EXPRESSION | 15 | 1733 | 4.227e-06 | 0.0001124 |
176 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 12 | 1087 | 4.357e-06 | 0.0001152 |
177 | RESPONSE TO GLUCAGON | 4 | 48 | 4.425e-06 | 0.0001163 |
178 | RESPONSE TO REACTIVE OXYGEN SPECIES | 6 | 191 | 4.781e-06 | 0.000125 |
179 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 4 | 49 | 4.81e-06 | 0.000125 |
180 | REGULATION OF NEURON APOPTOTIC PROCESS | 6 | 192 | 4.927e-06 | 0.0001274 |
181 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 5 | 109 | 5.03e-06 | 0.0001286 |
182 | CELLULAR CHEMICAL HOMEOSTASIS | 9 | 570 | 5.007e-06 | 0.0001286 |
183 | T CELL APOPTOTIC PROCESS | 3 | 15 | 5.082e-06 | 0.0001292 |
184 | RESPONSE TO DRUG | 8 | 431 | 5.549e-06 | 0.0001403 |
185 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 6.008e-06 | 0.0001511 |
186 | RESPONSE TO INTERLEUKIN 1 | 5 | 115 | 6.54e-06 | 0.0001636 |
187 | POSITIVE REGULATION OF TRANSPORT | 11 | 936 | 6.575e-06 | 0.0001636 |
188 | REGULATION OF DEFENSE RESPONSE | 10 | 759 | 6.89e-06 | 0.0001705 |
189 | FC RECEPTOR SIGNALING PATHWAY | 6 | 206 | 7.377e-06 | 0.0001816 |
190 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 3 | 17 | 7.57e-06 | 0.0001854 |
191 | LYMPHOCYTE APOPTOTIC PROCESS | 3 | 18 | 9.069e-06 | 0.0002209 |
192 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 4 | 58 | 9.487e-06 | 0.0002299 |
193 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 8 | 465 | 9.658e-06 | 0.0002328 |
194 | REGULATION OF INTRACELLULAR TRANSPORT | 9 | 621 | 9.983e-06 | 0.0002394 |
195 | RESPONSE TO ESTROGEN | 6 | 218 | 1.019e-05 | 0.0002419 |
196 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 218 | 1.019e-05 | 0.0002419 |
197 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 220 | 1.073e-05 | 0.0002535 |
198 | REGULATION OF GLUCOSE IMPORT | 4 | 60 | 1.087e-05 | 0.0002554 |
199 | LYMPHOCYTE ACTIVATION | 7 | 342 | 1.213e-05 | 0.0002837 |
200 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 11 | 1004 | 1.275e-05 | 0.0002967 |
201 | NECROPTOTIC PROCESS | 3 | 21 | 1.471e-05 | 0.0003405 |
202 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 6 | 233 | 1.487e-05 | 0.0003426 |
203 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 365 | 1.847e-05 | 0.0004232 |
204 | CELLULAR RESPONSE TO OXYGEN LEVELS | 5 | 143 | 1.886e-05 | 0.0004302 |
205 | LEUKOCYTE APOPTOTIC PROCESS | 3 | 23 | 1.953e-05 | 0.0004432 |
206 | I KAPPAB KINASE NF KAPPAB SIGNALING | 4 | 70 | 2.009e-05 | 0.0004517 |
207 | WATER HOMEOSTASIS | 4 | 70 | 2.009e-05 | 0.0004517 |
208 | RESPONSE TO ESTRADIOL | 5 | 146 | 2.085e-05 | 0.0004664 |
209 | NEGATIVE REGULATION OF KINASE ACTIVITY | 6 | 250 | 2.214e-05 | 0.0004928 |
210 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 381 | 2.432e-05 | 0.0005388 |
211 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 3 | 25 | 2.528e-05 | 0.0005574 |
212 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 2.853e-05 | 0.0006232 |
213 | REGULATION OF NECROTIC CELL DEATH | 3 | 26 | 2.853e-05 | 0.0006232 |
214 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 14 | 1805 | 3.392e-05 | 0.0007374 |
215 | INSULIN RECEPTOR SIGNALING PATHWAY | 4 | 80 | 3.408e-05 | 0.0007376 |
216 | NECROTIC CELL DEATH | 3 | 28 | 3.583e-05 | 0.0007718 |
217 | REGULATION OF CYTOKINE PRODUCTION | 8 | 563 | 3.812e-05 | 0.0008174 |
218 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 3 | 29 | 3.99e-05 | 0.0008516 |
219 | LEUKOCYTE ACTIVATION | 7 | 414 | 4.128e-05 | 0.000877 |
220 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 6 | 282 | 4.346e-05 | 0.0009191 |
221 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 30 | 4.426e-05 | 0.0009319 |
222 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 11 | 1152 | 4.557e-05 | 0.000955 |
223 | REGULATION OF PROTEIN LOCALIZATION | 10 | 950 | 4.773e-05 | 0.000996 |
224 | HOMEOSTASIS OF NUMBER OF CELLS | 5 | 175 | 4.966e-05 | 0.001027 |
225 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 4 | 88 | 4.958e-05 | 0.001027 |
226 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 1395 | 5.315e-05 | 0.001094 |
227 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 3 | 32 | 5.39e-05 | 0.0011 |
228 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 3 | 32 | 5.39e-05 | 0.0011 |
229 | CELL DEVELOPMENT | 12 | 1426 | 6.581e-05 | 0.001337 |
230 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 13 | 1672 | 6.861e-05 | 0.001388 |
231 | PROTEIN DEPHOSPHORYLATION | 5 | 190 | 7.336e-05 | 0.001478 |
232 | HEMOSTASIS | 6 | 311 | 7.476e-05 | 0.001499 |
233 | SINGLE ORGANISM CELL ADHESION | 7 | 459 | 7.907e-05 | 0.001579 |
234 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 5 | 195 | 8.293e-05 | 0.001649 |
235 | RESPONSE TO ACID CHEMICAL | 6 | 319 | 8.598e-05 | 0.001702 |
236 | SPLEEN DEVELOPMENT | 3 | 39 | 9.82e-05 | 0.001936 |
237 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 5 | 203 | 0.0001002 | 0.001968 |
238 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 3 | 40 | 0.000106 | 0.002063 |
239 | REGULATION OF CYTOPLASMIC TRANSPORT | 7 | 481 | 0.0001059 | 0.002063 |
240 | RESPONSE TO HYDROGEN PEROXIDE | 4 | 109 | 0.0001142 | 0.002214 |
241 | LYMPHOCYTE DIFFERENTIATION | 5 | 209 | 0.0001149 | 0.002219 |
242 | REGULATION OF NIK NF KAPPAB SIGNALING | 3 | 42 | 0.0001228 | 0.00236 |
243 | RESPONSE TO AMINO ACID | 4 | 112 | 0.0001269 | 0.002429 |
244 | RESPONSE TO STEROID HORMONE | 7 | 497 | 0.0001297 | 0.002473 |
245 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 13 | 1784 | 0.0001331 | 0.002527 |
246 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 6 | 351 | 0.000145 | 0.002743 |
247 | REGULATION OF TRANSPORT | 13 | 1804 | 0.0001489 | 0.002806 |
248 | THYMOCYTE AGGREGATION | 3 | 45 | 0.000151 | 0.002822 |
249 | T CELL DIFFERENTIATION IN THYMUS | 3 | 45 | 0.000151 | 0.002822 |
250 | CELLULAR COMPONENT DISASSEMBLY | 7 | 515 | 0.0001615 | 0.003007 |
251 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 4 | 120 | 0.0001655 | 0.003069 |
252 | RESPONSE TO ALCOHOL | 6 | 362 | 0.0001715 | 0.003167 |
253 | T CELL DIFFERENTIATION | 4 | 123 | 0.000182 | 0.003348 |
254 | REGULATION OF LIPID KINASE ACTIVITY | 3 | 48 | 0.0001832 | 0.003355 |
255 | INOSITOL LIPID MEDIATED SIGNALING | 4 | 124 | 0.0001878 | 0.003427 |
256 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 6 | 370 | 0.000193 | 0.003509 |
257 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 6 | 372 | 0.0001987 | 0.003598 |
258 | RESPONSE TO UV | 4 | 126 | 0.0001997 | 0.003601 |
259 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 3 | 50 | 0.0002069 | 0.003717 |
260 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 7 | 541 | 0.0002185 | 0.003895 |
261 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 7 | 541 | 0.0002185 | 0.003895 |
262 | RESPONSE TO NICOTINE | 3 | 51 | 0.0002195 | 0.003898 |
263 | REGULATION OF T CELL MEDIATED IMMUNITY | 3 | 52 | 0.0002325 | 0.004099 |
264 | REGULATION OF LIPID CATABOLIC PROCESS | 3 | 52 | 0.0002325 | 0.004099 |
265 | SINGLE ORGANISM BEHAVIOR | 6 | 384 | 0.0002358 | 0.004141 |
266 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 3 | 53 | 0.0002461 | 0.004305 |
267 | COGNITION | 5 | 251 | 0.0002694 | 0.004695 |
268 | RESPONSE TO ALKALOID | 4 | 137 | 0.0002751 | 0.004776 |
269 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 2 | 11 | 0.0002809 | 0.004817 |
270 | REGULATION OF ORGANELLE ORGANIZATION | 10 | 1178 | 0.0002816 | 0.004817 |
271 | REGULATION OF NECROPTOTIC PROCESS | 2 | 11 | 0.0002809 | 0.004817 |
272 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 2 | 11 | 0.0002809 | 0.004817 |
273 | NUCLEIC ACID PHOSPHODIESTER BOND HYDROLYSIS | 5 | 254 | 0.0002846 | 0.004851 |
274 | CELL ACTIVATION | 7 | 568 | 0.0002939 | 0.00499 |
275 | REGULATION OF VITAMIN METABOLIC PROCESS | 2 | 12 | 0.0003366 | 0.005634 |
276 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 2 | 12 | 0.0003366 | 0.005634 |
277 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 2 | 12 | 0.0003366 | 0.005634 |
278 | POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS | 2 | 12 | 0.0003366 | 0.005634 |
279 | IMMUNE SYSTEM DEVELOPMENT | 7 | 582 | 0.0003405 | 0.005678 |
280 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 9 | 983 | 0.0003437 | 0.005711 |
281 | CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 146 | 0.0003504 | 0.005782 |
282 | T CELL RECEPTOR SIGNALING PATHWAY | 4 | 146 | 0.0003504 | 0.005782 |
283 | PEPTIDYL SERINE MODIFICATION | 4 | 148 | 0.000369 | 0.006067 |
284 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 61 | 0.0003733 | 0.006115 |
285 | NEGATIVE REGULATION OF PHOSPHORYLATION | 6 | 422 | 0.0003905 | 0.006376 |
286 | HEPATOCYTE APOPTOTIC PROCESS | 2 | 13 | 0.0003972 | 0.006462 |
287 | CELL CELL ADHESION | 7 | 608 | 0.0004428 | 0.007178 |
288 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 4 | 156 | 0.0004504 | 0.007277 |
289 | PROTEIN OLIGOMERIZATION | 6 | 434 | 0.0004531 | 0.007295 |
290 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 7 | 616 | 0.0004788 | 0.007682 |
291 | DEPHOSPHORYLATION | 5 | 286 | 0.0004899 | 0.007834 |
292 | CELLULAR RESPONSE TO DRUG | 3 | 67 | 0.0004921 | 0.007841 |
293 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 289 | 0.0005137 | 0.008158 |
294 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 4 | 163 | 0.0005315 | 0.008381 |
295 | NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 2 | 15 | 0.0005331 | 0.008381 |
296 | NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 2 | 15 | 0.0005331 | 0.008381 |
297 | REGULATION OF CELLULAR LOCALIZATION | 10 | 1277 | 0.000535 | 0.008381 |
298 | LEUKOCYTE DIFFERENTIATION | 5 | 292 | 0.0005384 | 0.008406 |
299 | REGULATION OF INFLAMMATORY RESPONSE | 5 | 294 | 0.0005553 | 0.008641 |
300 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 3 | 71 | 0.0005833 | 0.009047 |
301 | CELLULAR RESPONSE TO LIPID | 6 | 457 | 0.0005948 | 0.009194 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CYTOKINE RECEPTOR BINDING | 10 | 271 | 4.69e-10 | 4.357e-07 |
2 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 6 | 47 | 1.055e-09 | 4.902e-07 |
3 | ENZYME BINDING | 18 | 1737 | 1.915e-08 | 5.932e-06 |
4 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 4 | 15 | 3.281e-08 | 7.62e-06 |
5 | DEATH RECEPTOR BINDING | 4 | 18 | 7.318e-08 | 1.36e-05 |
6 | KINASE REGULATOR ACTIVITY | 7 | 186 | 2.117e-07 | 3.278e-05 |
7 | DEATH RECEPTOR ACTIVITY | 4 | 24 | 2.516e-07 | 3.339e-05 |
8 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 4 | 30 | 6.423e-07 | 6.63e-05 |
9 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 4 | 30 | 6.423e-07 | 6.63e-05 |
10 | PROTEIN HETERODIMERIZATION ACTIVITY | 9 | 468 | 9.948e-07 | 8.401e-05 |
11 | KINASE BINDING | 10 | 606 | 9.229e-07 | 8.401e-05 |
12 | MOLECULAR FUNCTION REGULATOR | 14 | 1353 | 1.211e-06 | 8.651e-05 |
13 | ENZYME REGULATOR ACTIVITY | 12 | 959 | 1.184e-06 | 8.651e-05 |
14 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 5 | 86 | 1.559e-06 | 0.0001035 |
15 | KINASE ACTIVITY | 11 | 842 | 2.382e-06 | 0.0001475 |
16 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 4 | 42 | 2.571e-06 | 0.0001493 |
17 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 43 | 2.83e-06 | 0.0001547 |
18 | PROTEASE BINDING | 5 | 104 | 3.993e-06 | 0.0002061 |
19 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 5.082e-06 | 0.0002485 |
20 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 4 | 51 | 5.654e-06 | 0.0002626 |
21 | INTERLEUKIN 1 RECEPTOR BINDING | 3 | 16 | 6.244e-06 | 0.0002762 |
22 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 11 | 992 | 1.139e-05 | 0.000481 |
23 | CAMP BINDING | 3 | 23 | 1.953e-05 | 0.0007778 |
24 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 70 | 2.009e-05 | 0.0007778 |
25 | ENZYME INHIBITOR ACTIVITY | 7 | 378 | 2.312e-05 | 0.000859 |
26 | PROTEIN DIMERIZATION ACTIVITY | 11 | 1149 | 4.449e-05 | 0.00159 |
27 | KINASE INHIBITOR ACTIVITY | 4 | 89 | 5.183e-05 | 0.001783 |
28 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 5 | 184 | 6.302e-05 | 0.002086 |
29 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 7 | 445 | 6.511e-05 | 0.002086 |
30 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 7.709e-05 | 0.002387 |
31 | PROTEIN KINASE ACTIVITY | 8 | 640 | 9.373e-05 | 0.002721 |
32 | RECEPTOR BINDING | 12 | 1476 | 9.176e-05 | 0.002721 |
33 | PROTEIN KINASE A BINDING | 3 | 42 | 0.0001228 | 0.003456 |
34 | PEPTIDASE REGULATOR ACTIVITY | 5 | 214 | 0.0001284 | 0.003508 |
35 | PROTEIN PHOSPHATASE BINDING | 4 | 120 | 0.0001655 | 0.004394 |
36 | IDENTICAL PROTEIN BINDING | 10 | 1209 | 0.0003467 | 0.008948 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MEMBRANE MICRODOMAIN | 10 | 288 | 8.464e-10 | 4.943e-07 |
2 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 9 | 237 | 2.978e-09 | 8.696e-07 |
3 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 4 | 20 | 1.155e-07 | 2.248e-05 |
4 | CILIARY BASE | 4 | 23 | 2.1e-07 | 3.066e-05 |
5 | CATALYTIC COMPLEX | 13 | 1038 | 3.776e-07 | 4.41e-05 |
6 | PROTEIN KINASE COMPLEX | 5 | 90 | 1.955e-06 | 0.0001882 |
7 | MEMBRANE PROTEIN COMPLEX | 12 | 1020 | 2.256e-06 | 0.0001882 |
8 | TRANSFERASE COMPLEX | 9 | 703 | 2.67e-05 | 0.001949 |
9 | MEMBRANE REGION | 11 | 1134 | 3.946e-05 | 0.00256 |
10 | PLASMA MEMBRANE PROTEIN COMPLEX | 7 | 510 | 0.0001521 | 0.008884 |
11 | PHOSPHATASE COMPLEX | 3 | 48 | 0.0001832 | 0.009725 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 46 | 89 | 4.089e-115 | 7.361e-113 | |
2 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 15 | 136 | 5.948e-22 | 5.354e-20 | |
3 | hsa04662_B_cell_receptor_signaling_pathway | 12 | 75 | 1.08e-19 | 6.481e-18 | |
4 | hsa04722_Neurotrophin_signaling_pathway | 13 | 127 | 1.24e-18 | 4.959e-17 | |
5 | hsa04380_Osteoclast_differentiation | 13 | 128 | 1.378e-18 | 4.959e-17 | |
6 | hsa04660_T_cell_receptor_signaling_pathway | 12 | 108 | 1.095e-17 | 3.284e-16 | |
7 | hsa04370_VEGF_signaling_pathway | 11 | 76 | 1.345e-17 | 3.459e-16 | |
8 | hsa04010_MAPK_signaling_pathway | 15 | 268 | 1.922e-17 | 4.326e-16 | |
9 | hsa04620_Toll.like_receptor_signaling_pathway | 11 | 102 | 4.012e-16 | 8.025e-15 | |
10 | hsa04910_Insulin_signaling_pathway | 11 | 138 | 1.223e-14 | 2.201e-13 | |
11 | hsa04151_PI3K_AKT_signaling_pathway | 12 | 351 | 1.612e-11 | 2.638e-10 | |
12 | hsa04510_Focal_adhesion | 10 | 200 | 2.379e-11 | 3.568e-10 | |
13 | hsa04014_Ras_signaling_pathway | 10 | 236 | 1.215e-10 | 1.683e-09 | |
14 | hsa04062_Chemokine_signaling_pathway | 9 | 189 | 4.047e-10 | 5.203e-09 | |
15 | hsa04973_Carbohydrate_digestion_and_absorption | 6 | 44 | 6.974e-10 | 8.369e-09 | |
16 | hsa04914_Progesterone.mediated_oocyte_maturation | 7 | 87 | 1.075e-09 | 1.21e-08 | |
17 | hsa04150_mTOR_signaling_pathway | 6 | 52 | 1.984e-09 | 2.101e-08 | |
18 | hsa04115_p53_signaling_pathway | 6 | 69 | 1.135e-08 | 1.135e-07 | |
19 | hsa04664_Fc_epsilon_RI_signaling_pathway | 6 | 79 | 2.586e-08 | 2.45e-07 | |
20 | hsa04012_ErbB_signaling_pathway | 6 | 87 | 4.634e-08 | 4.171e-07 | |
21 | hsa04630_Jak.STAT_signaling_pathway | 7 | 155 | 6.088e-08 | 5.219e-07 | |
22 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 6 | 95 | 7.867e-08 | 6.436e-07 | |
23 | hsa04621_NOD.like_receptor_signaling_pathway | 5 | 59 | 2.348e-07 | 1.837e-06 | |
24 | hsa04920_Adipocytokine_signaling_pathway | 5 | 68 | 4.814e-07 | 3.61e-06 | |
25 | hsa04720_Long.term_potentiation | 5 | 70 | 5.57e-07 | 4.01e-06 | |
26 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 4 | 42 | 2.571e-06 | 1.78e-05 | |
27 | hsa04114_Oocyte_meiosis | 5 | 114 | 6.266e-06 | 4.178e-05 | |
28 | hsa04622_RIG.I.like_receptor_signaling_pathway | 4 | 71 | 2.126e-05 | 0.0001367 | |
29 | hsa04310_Wnt_signaling_pathway | 5 | 151 | 2.452e-05 | 0.0001522 | |
30 | hsa04070_Phosphatidylinositol_signaling_system | 4 | 78 | 3.084e-05 | 0.0001851 | |
31 | hsa04020_Calcium_signaling_pathway | 5 | 177 | 5.242e-05 | 0.0003044 | |
32 | hsa04670_Leukocyte_transendothelial_migration | 4 | 117 | 0.0001502 | 0.0008446 | |
33 | hsa04360_Axon_guidance | 4 | 130 | 0.0002251 | 0.001228 | |
34 | hsa04623_Cytosolic_DNA.sensing_pathway | 3 | 56 | 0.0002898 | 0.001534 | |
35 | hsa04810_Regulation_of_actin_cytoskeleton | 4 | 214 | 0.001463 | 0.007524 | |
36 | hsa04640_Hematopoietic_cell_lineage | 2 | 88 | 0.01748 | 0.08738 | |
37 | hsa04530_Tight_junction | 2 | 133 | 0.03755 | 0.1827 | |
38 | hsa04120_Ubiquitin_mediated_proteolysis | 2 | 139 | 0.04068 | 0.1927 | |
39 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 2 | 168 | 0.05707 | 0.2634 |